ResMed Inc. (CHESS) Given Buy Rating at UBS AG (RMD)
ResMed Inc. (CHESS) (ASX:RMD)‘s stock had its “buy” rating reiterated by analysts at UBS AG in a research report issued to clients and investors on Wednesday, AnalystRatingsNetwork.com reports. They currently have a $415.00 price objective on the stock.
ResMed Inc. (ASX:RMD) traded down 1.46% on Wednesday, hitting A$5.410. The stock had a trading volume of 320,000 shares. ResMed Inc. has a 1-year low of A$3.580 and a 1-year high of A$5.550. The stock’s 50-day moving average is A$5.17 and its 200-day moving average is A$4.75. The company has a market cap of A$7.685 billion and a P/E ratio of 26.14.
ResMed Inc, (ASX:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.